Nyxoah (NYXH) Q4 2025: U.S. Genio Launch Drives 122% Revenue Growth, Sales Force Expands to 40

2026-03-19 | By EarningsIQ Research

Nyxoah’s first full quarter of Genio’s U.S. launch delivered rapid commercial traction and marked a pivotal transformation into a commercial-stage company. Aggressive sales force expansion and clear reimbursement pathways underpin the company’s U.S. growth strategy, while margin and cash burn dynamics remain key watchpoints. Investors should monitor Genio’s real-world adoption rates and the pace of new account activations as the company scales toward national coverage.

Summary

• Genio U.S. Launch Momentum: Commercial execution accelerated with rapid account activation and positive physician feedback.
• Reimbursement Clarity Secured: CMS and commercial payer coverage for Genio removes adoption barriers for both hospitals and surgeons.
• Sales Force Scaling: Expanded U.S. team positions Nyxoah to double account coverage in 2026, driving market share capture.

Performance Analysis

Nyxoah’s transition from pre-commercial to commercial-stage company was evident in Q4, as U.S. Genio sales accounted for the majority of quarterly revenue and drove a 122% year-over-year increase in annual net revenue. The company generated €5.6 million in net revenue for the quarter, with €3.5 million attributed to the U.S. launch, while gross margin reached 64%. Operating loss remained relatively stable at €18.6 million despite the ramp in commercial investment, signaling disciplined cost control as the company scaled its U.S. operations.

Internationally, Germany reached profitability and other markets contributed consistent revenue, but the U.S. remains the primary engine for growth and scale. The cash position at year-end stood at €48 million, with recent capital raises providing runway into early 2027 despite a near-term quarterly cash burn of approximately €20 million. The company deferred €0.7 million in revenue due to the timing of disposable patch deliveries, reflecting the recurring nature of Genio’s business model, which blends implant sales with ongoing consumables.

• U.S. Commercialization Drives Top-Line: Q4 marked the first full quarter of Genio sales in the U.S., catalyzing outsized revenue growth.
• Margin Resilience Amid Expansion: Gross margin held at 64% during the launch, with further improvement expected as volume scales and manufacturing footprint expands.
• Cash Burn Remains Elevated: Quarterly cash burn of €20 million is projected to decrease as revenue ramps, but remains a key metric for sustainability.

Nyxoah’s performance in Q4 validates initial U.S. demand for Genio and demonstrates early operational leverage, but sustained sales productivity and cash discipline will be crucial as the company targets broader market penetration.

Executive Commentary

Strategic Positioning

1. U.S. Market Entry and Sales Force Expansion

Nyxoah’s deliberate U.S. launch strategy targeted the top 400 hypoglossal nerve stimulation (HGNS) accounts, focusing initial sales resources on the highest-volume opportunities. The company increased its U.S. sales force from 25 to 40 representatives in early 2026, expanding coverage from 125 to 200 accounts, or half of its total target market. This coverage model—where each rep manages five accounts—enables deep relationship-building and surgeon training, a critical lever for procedural adoption in the medtech space.

2. Reimbursement and Coding Clarity

Genio secured both Medicare and commercial payer reimbursement, representing 10% and 90% of Q4 business, respectively. The recent establishment of a CMS facility fee for Genio ($31,526 per procedure) brings parity with competitors and removes a key barrier to hospital adoption. The company is also actively engaged with coding authorities to secure dedicated CPT codes for the long term, with a likely transition to unique coding by 2028.

3. Differentiated Product Positioning

Genio’s bilateral stimulation and battery-free, single-incision design distinguish it from pacemaker-based competitors. Surgeon and patient feedback highlight ease of use, lower surgical burden, and consistent therapy efficacy across all sleeping positions as key adoption drivers. The company’s focus on patient-centric features—such as MRI compatibility and upgradable software—strengthens its value proposition in a market accustomed to legacy technologies.

4. International Profitability and Platform Leverage

International markets, while secondary to the U.S., provide stable revenue and a proving ground for profitability, with Germany already achieving this milestone. The company’s expansion of internal manufacturing aims to further improve gross margin and operational control, setting the stage for future product iterations and cost reductions, particularly with the next-generation disposable patch in 2027.

Key Considerations

Nyxoah’s Q4 reflected not just launch momentum, but a foundational shift in commercial scale, reimbursement certainty, and market access. The following considerations frame the company’s evolving risk and opportunity set:

• Account Activation Funnel: The pace of Value Analysis Committee (VAC) approvals and new account activations will be the leading indicator for sustained U.S. growth.
• Sales Rep Productivity: Early productivity metrics are strong, but maintaining rep effectiveness as coverage doubles will test commercial execution.
• Reimbursement Environment: Clarity on both facility and physician fees de-risks near-term adoption, but long-term coding changes could alter competitive dynamics.
• Gross Margin Trajectory: Margin expansion is expected as volume scales and new manufacturing capabilities come online, but cost discipline remains essential until recurring revenue from consumables matures.
• Cash Runway and Capital Needs: With €48 million in cash and a €20 million quarterly burn, Nyxoah must demonstrate a credible path to cash flow breakeven as it invests in U.S. growth.

Risks

Nyxoah faces execution risk as it rapidly scales its U.S. sales force and expands into new accounts, with potential for uneven productivity or delays in account activation. The evolving reimbursement landscape introduces uncertainty around future coding and payment rates, while competition from established players and new entrants (such as Livanova) could pressure pricing or slow adoption. Continued high cash burn and the need for incremental capital remain prominent risks if revenue ramp lags expectations.

Forward Outlook

For Q1 and Q2 2026, Nyxoah guided to:

• 25% sequential net revenue growth in the U.S. for both quarters
• International revenue following typical seasonal patterns

For full-year 2026, management expects:

• Continued U.S. market share gains driven by sales force expansion and new account coverage
• Gross margin to improve modestly, with a step function increase expected in 2027 following the launch of Genio 2.2 disposable patch

Management highlighted several factors that will shape 2026:

• More than doubling U.S. account coverage to 200 of the top 400 HGNS sites
• Ongoing investments in surgeon training and patient referral networks
• Progress toward label expansion via the EXCESS clinical study, with 12-month data expected by July 2026 and PMA supplement submission targeted for late summer

Takeaways

Nyxoah’s Q4 marked a decisive shift into commercial execution, with U.S. Genio adoption and reimbursement clarity setting the stage for accelerated growth in 2026.

• Commercial Traction Validated: Early U.S. sales productivity and account activation support the company’s differentiated positioning and growth thesis.
• Margin and Cash Burn in Focus: Gross margin held up during launch, but investors should monitor the pace of improvement and capital discipline as the sales force expands.
• Watch for Account Ramp and Clinical Milestones: The pace of new account activations and the outcome of the EXCESS study will shape both near-term revenue and longer-term label expansion potential.

Conclusion

Nyxoah’s Q4 results demonstrated robust U.S. launch execution, strong commercial uptake, and a clear path to broader market penetration, though the company must now prove it can scale efficiently and manage capital as competition intensifies and operational complexity rises.

Industry Read-Through

Nyxoah’s rapid U.S. launch and reimbursement wins highlight the importance of payer clarity and targeted account activation in medtech commercialization. The company’s approach—prioritizing top-volume centers, investing in sales force productivity, and leveraging differentiated product features—offers a blueprint for other device innovators entering established but evolving therapeutic markets. The evolving coding landscape and the rise of alternatives to legacy pacemaker-based HGNS systems signal intensifying competition and a shift toward patient-centric device attributes. Investors across the neurostimulation and sleep apnea device sectors should monitor how payer frameworks and account funnel dynamics shape adoption curves for new entrants.

NYXH Healthcare Medical Devices Commercialization Reimbursement Sleep Apnea Gross Margin Account Activation